Johnson & Johnson: A Healthcare Stock Safer Than Treasury Bonds

According to an analysis published by 24/7 Wall St., Johnson & Johnson (JNJ) is a rare equity that investors can buy and never sell, thanks to its ability to compound capital over the long term with extremely low credit risk.

Why JNJ Is Safer Than Treasury Bonds

Analysts point to three rare characteristics that make JNJ a rival to government bonds:

• High credit quality: Excellent credit rating supporting financial stability.
• Unmatched dividend record: Decades of consistent dividend increases.
• Inelastic demand: Healthcare is the one expense Americans cannot defer, ensuring stable cash flows.

Analyst's Rationale

The analysis notes that JNJ sits at the center of healthcare spending, a sector immune to economic cycles. This gives the stock a "bond-like" advantage, allowing investors to rely on steady returns and capital appreciation with lower volatility.

Context

Unlike Treasury bonds, which offer fixed but limited yields, JNJ provides potential for capital growth alongside rising dividends. This makes it an attractive option for income-seeking investors looking for long-term growth.

What We Conclude

While the analysis does not explicitly recommend buying, it underscores JNJ's unique position as a defensive long-term holding. Investors seeking stability and dividends may find it an appealing alternative to bonds, but they should assess their own risk tolerance before making any decision.